Table 2Trials of dual therapy with pegylated interferon alfa-2a plus ribavirin versus dual therapy with pegylated interferon alfa-2b plus ribavirin

Trial
Country
N
Quality
Population CharacteristicsGenotype MixWeekly Pegylated Interferon DoseDaily Ribavirin DoseDuration (weeks)Sustained Virologic Response Rate
Ascione, 201020
Italy
N=320

Quality: Fair
A vs. B
Age (mean): 51 vs. 49 years
Female: 49% vs. 61%
Race: Not reported
Cirrhosis: 21% vs. 16%
Minimal or no fibrosis: Not reported
Elevated transaminases: 100%
~60% genotype 1 or 4A. Alfa-2a 180 mcg
B. Alfa-2b 1.5 mcg/kg
1000–1200 mg24–48 by genotypeA. 69%
B. 54%
Escudero, 200821
Spain
N=183

Quality: Poor
A vs. B
Age (mean): 44 vs. 44 years
Female: 30% vs. 39%
Race: Not reported
Cirrhosis: Not reported
Minimal or no fibrosis: Not reported (100% had at least periportal fibrosis)
Elevated transaminases: 100%
~75% genotype 1 or 4A. Alfa-2a 180 mcg
B. Alfa-2b 1.5 mcg/kg
800–1200 mg24–48 by genotypeA. 66%
B. 62%
Kamal, 201153
Egypt
N=217

Quality: Fair
A vs. B
Age (mean): 42 vs. 41 years
Female: 46% vs. 56%
Race: Not reported
Cirrhosis: Not reported
Minimal or no fibrosis: Not reported
Elevated transaminases: 100%
100% genotype 4A. Alfa-2a 180 mcg
B. Alfa-2b 1.5 mcg/kg
1000–1200 mg48A. 71%
B. 55%
Khan, 200754
Pakistan
N=66

Quality: Not assessedb
A vs. B
Age: Not reported
Female: Not reported
Race: Not reported
Cirrhosis: Not reported
Minimal or no fibrosis: Not reported
Elevated transaminases: Not reported
100% genotype 3A. Alfa-2a 180 mcg
B. Alfa-2b 1.0 mcg/kg
800 mg24A. 79%
B. 82%
Mach 201155
Poland
N=260

Quality: Fair
A vs. B
Age: 44 vs. 45.2 years
Female: 37.7% vs. 42%
Race: Not reported (Polish centers)
Cirrhosis: Not reported
Minimal or no fibrosis: Not reported (78% vs. 73% F0–F2 fibrosis)
Elevated transaminases: Not reported
100% genotype 1bA: Alfa-2a 180 mcg
B:Alfa-2b 1.5 mg/kg
1000–1200 mg48A. 49%
B. 44%
Magni, 200956
Italy
N=218

Quality: Not assessedb
A vs. B
Age: Not reported
Female: Not reported
Race: Not reported
Cirrhosis: Not reported
Minimal or no fibrosis: Not reported
Elevated transaminases: Not reported
~55% genotype 1 or 4A. Alfa-2a 180 mcg
B. Alfa-2b 1.5 mcg/kg
10.5 mg/kg24–48 by genotypeA. 68%
B. 67%
Marcellin, 201159a
Europe
N=161

Quality: Fair
A vs. B vs. C vs. D
Age (median): 47 vs. 46 vs. 40 vs. 49 years
Female: 50% vs. 52% vs. 48% vs. 51
Non-White race: 10% vs. 10% vs. 10% vs. 8%
Cirrhosis: 2.5% vs. 2.4% vs. 0% vs. 5.1%
Minimal or no fibrosis: 38% vs. 36% vs. 55% vs. 28%
Elevated transaminases: Not reported
100% genotype 1A. Alfa-2a 180 mcg
B. Alfa-2b 1.5 mcg/kg
C. Alfa-2a 180 mcg
D. Alfa-2b 1.5 mcg/kg
A. 1000–1200 mg
B. 800–1200 mg
C. 1000–1200 mg
D. 800–1200 mg
24/48A. 85%
B. 81%
C. 83%
D. 82%
McHutchison, 2008 (IDEAL)60
U.S.
N=3070

Quality: Fair
A vs. B vs. C
Age (mean): 48 vs. 48 vs. 48 years
Female: 40% vs. 40% vs. 41%
Non-White race: 29% vs. 28% vs. 29%
Cirrhosis: Not reported (10% vs. 11% vs. 11% severe fibrosis or cirrhosis)
Minimal or no fibrosis: Not reported
Elevated transaminases: 80% vs. 81% vs. 81%
100% genotype 1A. Alfa-2a 180 mcg
B. Alfa-2b 1.5 mcg/kg
C. Alfa-2b 1.0 mcg/kg
A. 1000–1200 mg
B. 800–1400 mg
C. 800–1400 mg
48
A. 41%
B. 40%
C. 38%
Miyase, 201257
Japan
N=201

Quality: Fair
A vs. B
Age mean: 59.2 vs. 58.9 years
Female: 61.4% vs. 60%
Nonwhite race: Not reported
Cirrhosis: 20% vs. 17%
Minimal or no fibrosis: Not reported
Elevated transaminases: Not reported
100% genotype 1A: Alfa-2a 180 mcg

B: Alfa-2b 60–150 mcg/kg (weight-based)
600–1000 mg48A. 66%
B. 51%
Rumi, 201023
Italy
N=431

Quality: Fair
A vs. B
Age (mean): 52 vs. 53 years
Female: 40% vs. 45%
Race: Not reported
Cirrhosis: 20% vs. 18%
Minimal or no fibrosis: Not reported
Elevated transaminases (>2 times upper limit of normal): 59% vs. 59%
41% genotype 1
33% genotype 2
15% genotype 3
10% genotype 4
A. Alfa-2a 180 mcg

B. Alfa-2b 1.5 mcg/kg
Genotype 1/4:
A. 1000–1200 mg/day for 48 weeks

B. 800–1200 mg/day for 48 weeks

Genotype 2/3:
A. 800 mg/day for 24 weeks

B. 800–1200 mg/day for 24 weeks
24–48 by genotypeA: 66%

B: 54%
Yenice, 200658
Turkey
N=74

Quality: Poor
A vs. B
Age (mean): 48 vs. 51 years
Female: 35% vs. 27%
Race: Not reported
Cirrhosis: Not reported
Minimal or no fibrosis: Not reported (all patients had at least minimal fibrosis)
Elevated transaminases: 70% vs. 76%
100% genotype 1 (1a vs. 1b vs. 1c)A. Alfa-2a 180 mcg
B. Alfa-2b 1.5 mcg/kg
800–1200 mg24–48 by genotypeA. 49%
B. 35%

Note: Cirrhosis = METAVIR F4, Ishak 5–6, or equivalent. Minimal or no fibrosis=METAVIR F0–F1, Ishak 0–2, or equivalent.

a

All arms included 12 weeks of telaprevir; because this trial compared triple therapy regimens it was excluded from the primary analysis and only included in sensitivity analysis.

b

Published as abstract only; only included in sensitivity analysis.

From: Results

Cover of Treatment for Hepatitis C Virus Infection in Adults
Treatment for Hepatitis C Virus Infection in Adults [Internet].
Comparative Effectiveness Reviews, No. 76.
Chou R, Hartung D, Rahman B, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.